Afatinib (BIBW2992)

Name: Afatinib (BIBW2992)
Brand: Selleck Chemicals
SKU: S1011
Rating: 5 (180 reviews)

For research use only. Not for use in humans.

Catalog No.S1011

180 publications

Molecular Weight(MW): 485.94

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively.

Selleck's Afatinib (BIBW2992) has been cited by 180 publications

Nature, 2019, 571(7763):127-131

PubMed: 31243371 ( click the link to review the publication )

Nat Med, 2019, 25(1):111-118

PubMed: 30478424 ( click the link to review the publication )

Cancer Discov, 2019, 9(7):926-943

PubMed: 31092401 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 10.1016/j.ccell.2019.09.001

PubMed: 31588020 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Nat Med, 2018, 24(5):638-646

PubMed: 29686424 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Methods, 2018, 15(8):631-639

PubMed: 30038414 ( click the link to review the publication )

Nat Med, 2017, 23(10):1167-1175

PubMed: 28920960 ( click the link to review the publication )

Nature, 2016, 534(7609):647-51

PubMed: 27338794 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Cancer Discov, 2013, 3(2):168-81

PubMed: 23229345 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nano Lett, 2019, 19(10):7526-7533

PubMed: 31487192 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(9):1556-1566

PubMed: 31108249 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31776128 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32487

PubMed: 31162839 ( click the link to review the publication )

Oncogene, 2019, 38(30):5890-5904

PubMed: 31253872 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):282

PubMed: 31262325 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):266

PubMed: 31215502 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)

PubMed: 30609749 ( click the link to review the publication )
Cancers (Basel), 2019, 11(6)

PubMed: 31181806 ( click the link to review the publication )

Cell Death Dis, 2019, 10(9):663

PubMed: 31506424 ( click the link to review the publication )

Br J Cancer, 2019, 121(10):846-856

PubMed: 31607750 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):733-742

PubMed: 30787176 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):920-928

PubMed: 30872380 ( click the link to review the publication )

J Cancer, 2019, 10(9):2063-2073

PubMed: 31205567 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(6):1282-1292

PubMed: 31285959 ( click the link to review the publication )

Oncogenesis, 2019, 8(10):54

PubMed: 31570699 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(11):2233-2243

PubMed: 31467113 ( click the link to review the publication )

Gynecol Oncol, 2019, 153(1):158-164

PubMed: 30630630 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.28881

PubMed: 31152452 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )

Clin Lung Cancer, 2019, 20(3):167-177

PubMed: 30885551 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4488-4497

PubMed: 30679314 ( click the link to review the publication )

Mol Pharmacol, 2019, 95(5):528-536

PubMed: 30858165 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0248-2

PubMed: 31171828 ( click the link to review the publication )

Front Physiol, 2019, 10:189

PubMed: 30971932 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):951-962

PubMed: 30309221 ( click the link to review the publication )

Transl Oncol, 2019, 12(6):852-858

PubMed: 31030101 ( click the link to review the publication )

Oncol Rep, 2019, 41(2):1059-1066

PubMed: 30483795 ( click the link to review the publication )

Clin Otolaryngol, 2019, 10.1111/coa.13434

PubMed: 31536667 ( click the link to review the publication )
Mol Med Rep, 2019, 20(4):3317-3325

PubMed: 31432165 ( click the link to review the publication )

Pharmaceuticals (Basel), 2019, 12(4)

PubMed: 31703435 ( click the link to review the publication )

JCI Insight, 2019, 4(4)

PubMed: 30830869 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Oncotarget, 2019, 10(14):1440-1457

PubMed: 30858928 ( click the link to review the publication )

JCI Insight, 2019, 4(21)

PubMed: 31600169 ( click the link to review the publication )

J Am Chem Soc, 2018, 140(40):12785-12797

PubMed: 30256630 ( click the link to review the publication )

Nat Struct Mol Biol, 2018, 25(6):454-462

PubMed: 29760531 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(11):2594-2604

PubMed: 29298799 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Genes Dev, 2018, 32(17-18):1201-1214

PubMed: 30143526 ( click the link to review the publication )

Cancer Immunol Res, 2018, 6(12):1511-1523

PubMed: 30242021 ( click the link to review the publication )

Theranostics, 2018, 8(12):3176-3188

PubMed: 29930721 ( click the link to review the publication )

Cancer Res, 2018, 78(24):6866-6880

PubMed: 30322862 ( click the link to review the publication )

Oncogene, 2018, 37(12):1576-1593

PubMed: 29326440 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

EBioMedicine, 2018, 29:112-127

PubMed: 29433983 ( click the link to review the publication )

Cancers (Basel), 2018, 10(6)

PubMed: 29925812 ( click the link to review the publication )

Cancer Discov, 2018, 8(9):1087-1095

PubMed: 29802158 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(8):1648-1658

PubMed: 29748209 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2144-2155

PubMed: 30065098 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):2024-2033

PubMed: 29959202 ( click the link to review the publication )

Mol Oncol, 2018, 12(6):830-854

PubMed: 29603584 ( click the link to review the publication )
Mol Oncol, 2018, 12(4):441-462

PubMed: 29325228 ( click the link to review the publication )

Cancer Sci, 2018, 109(11):3657-3661

PubMed: 30255614 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Lung Cancer, 2018, 126:72-79

PubMed: 30527195 ( click the link to review the publication )

Front Oncol, 2018, 8:432

PubMed: 30345256 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14896

PubMed: 30291293 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

J Biol Chem, 2018, 293(42):16518-16527

PubMed: 30166343 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(8):1541-1550

PubMed: 30210922 ( click the link to review the publication )

Ann Thorac Surg, 2018, 105(2):363-370

PubMed: 29223420 ( click the link to review the publication )

Int J Oncol, 2018, 53(4):1544-1556

PubMed: 30066854 ( click the link to review the publication )

Invest New Drugs, 2018, 36(6):999-1005

PubMed: 29594878 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Biosci Rep, 2018, 38(6)

PubMed: 30420490 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:8201-8209

PubMed: 30568455 ( click the link to review the publication )

J Craniomaxillofac Surg, 2018, 46(3):492-497

PubMed: 29311018 ( click the link to review the publication )

Bladder Cancer, 2018, 4(1):77-90

PubMed: 29430509 ( click the link to review the publication )

Oncotarget, 2018, 9(9):8560-8572

PubMed: 29492217 ( click the link to review the publication )

Nat Commun, 2017, 8(1):410

PubMed: 28871105 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28145866 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

Oncogene, 2017, 36(13):1873-1886

PubMed: 27694893 ( click the link to review the publication )
Oncogene, 2017, 36(48):6691-6700

PubMed: 28745317 ( click the link to review the publication )

Cell Death Dis, 2017, 8(5):e2773

PubMed: 28492539 ( click the link to review the publication )

Neoplasia, 2017, 19(12):1012-1021

PubMed: 29136529 ( click the link to review the publication )

Sci Rep, 2017, 7:44206

PubMed: 28287179 ( click the link to review the publication )

Sci Rep, 2017, 7:44089

PubMed: 28276478 ( click the link to review the publication )

Cancer Prev Res, 2017, 10(1):76-88

PubMed: 27756753 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 335:16-27

PubMed: 28942004 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(4):1027-1033

PubMed: 28366635 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 491(3):656-661

PubMed: 28756224 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(14):22414-22432

PubMed: 26461472 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47305-47316

PubMed: 28521301 ( click the link to review the publication )

Oncotarget, 2017, 8(38):63901-63910

PubMed: 28969039 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

BMB Rep, 2017, 50(3):150-155

PubMed: 28256196 ( click the link to review the publication )

Gut, 2016, 1296-305

PubMed: 26001389 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Expert Opin Drug Deliv, 2016, 13(1):133-41

PubMed: 26371512 ( click the link to review the publication )

Mol Pharm, 2016, 13(6):2117-25

PubMed: 27169328 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(8):1708-19

PubMed: 27648360 ( click the link to review the publication )

Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )
PLoS One, 2016, 11(1):e0146311

PubMed: 26735495 ( click the link to review the publication )

Mol Med Rep, 2016, 13(3):2338-44

PubMed: 26782932 ( click the link to review the publication )

Oncotarget, 2016, 7(28):42859-42872

PubMed: 27374095 ( click the link to review the publication )

Oncotarget, 2016, 7(36):58038-58050

PubMed: 27487128 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )

Oncotarget, 2016, 7(26):40398-40417

PubMed: 27259258 ( click the link to review the publication )

Oncotarget, 2016, 7(50):83424-83436

PubMed: 27825137 ( click the link to review the publication )

Gut, 2015, 10.1136/gutjnl-2014-309026

PubMed: ( click the link to review the publication )

Nat Commun, 2015, 6:8481

PubMed: 26412466 ( click the link to review the publication )

J Thorac Oncol, 2015, 10(1):93-101

PubMed: 25384171 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(20):4597-606

PubMed: 26138066 ( click the link to review the publication )

Int J Cancer, 2015, 136(11):2717-29

PubMed: ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(1):298-306

PubMed: 25344583 ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-13-0951

PubMed: 25589492 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(3):375-84

PubMed: ( click the link to review the publication )

Cell Tissue Res, 2015, 359(3):799-816

PubMed: ( click the link to review the publication )

Oncol Rep, 2015, 34(6):2864-70

PubMed: 26503698 ( click the link to review the publication )

Oncol Rep, 2015, 34(6):2864-70

PubMed: 26503698 ( click the link to review the publication )

Arch Immunol Ther Exp, 2015, 10.1007/s00005-015-0330-5

PubMed: 25678473 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123623

PubMed: 25853726 ( click the link to review the publication )
Anticancer Res, 2015, 35(4):2005-8

PubMed: 25862853 ( click the link to review the publication )

J Anal Methods Chem, 2015, 2015:215128

PubMed: 26101692 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(10):972-7

PubMed: 25173978 ( click the link to review the publication )

Nat Commun, 2014, 5:5232

PubMed: 25366117 ( click the link to review the publication )

J Natl Cancer Inst, 2014, 106(9)

PubMed: 25214559 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(21):5423-34

PubMed: 25189483 ( click the link to review the publication )

Cancer Res, 2014, 74(1):341-52

PubMed: 24177178 ( click the link to review the publication )

Oncogene, 2014, 33(25):3334-41

PubMed: 23873022 ( click the link to review the publication )

Anal Chem, 2014, 86(21):10568-75

PubMed: 25263480 ( click the link to review the publication )

Br J Cancer, 2014, 111(9):1750-6

PubMed: 25268372 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(9):1239-47

PubMed: 24971884 ( click the link to review the publication )

Histochem Cell Biol, 2014, 142(4):361-71

PubMed: 24824474 ( click the link to review the publication )

Target Oncol, 2014, 10.1007/s11523-014-0344-7

PubMed: 25341405 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10503-17

PubMed: 25361177 ( click the link to review the publication )

Genes Cancer, 2014, 5(7-8):261-72

PubMed: 25221644 ( click the link to review the publication )

Drug Metab Lett, 2014, 8(1):19-30

PubMed: 24628405 ( click the link to review the publication )

Oncotarget, 2014, 5(24):12877-90

PubMed: 25375092 ( click the link to review the publication )

Drug Metab Lett, 2014, 8(1):19-30

PubMed: 24628405 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(10):972-7

PubMed: 25173978 ( click the link to review the publication )

Oncotarget, 2014, 5(15):5908-19

PubMed: 25115383 ( click the link to review the publication )

Sci Transl Med, 2013, 5(199):199ra111

PubMed: 23966300 ( click the link to review the publication )

Eur J Cancer, 2013, 49(6):1458-66

PubMed: 23153706 ( click the link to review the publication )

Oncogene, 2013, 32(37):4427-35

PubMed: 23045273 ( click the link to review the publication )
Cancer Sci, 2013, 104(5):584-9

PubMed: 23387505 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1618-25

PubMed: 24112719 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(6):537-45

PubMed: 23760496 ( click the link to review the publication )

PLoS One, 2013, 8(12):e84700

PubMed: 24386407 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56567

PubMed: 23451056 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(6):1663-71

PubMed: 22317763 ( click the link to review the publication )

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )

PLoS One, 2012, 7(7):e41017

PubMed: 22815900 ( click the link to review the publication )

Oncol Res, 2011, 19(10-11):471-8

PubMed: 22715590 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively.

Targets

EGFR (L858R) ^[1] (Cell-free assay)	EGFR (wt) ^[1] (Cell-free assay)	ErbB4 ^[2] (Cell-free assay)	EGFR (L858R/T790M) ^[1] (Cell-free assay)	HER2 ^[1] (Cell-free assay)
0.4 nM	0.5 nM	1 nM	10 nM	14 nM

In vitro

BIBW2992 shows potent activity against both wild-type and mutant forms of EGFR and HER2. It is similar to Gefitinib in potency against L858R EGFR, but about 100-fold more active against the Gefitinib resistant L858R-T790M EGFR double mutant. BIBW2992 exhibits potent effects on both EGFR and HER2 phosphorylation in vivo. It compares favorably to reference compounds (such as Lapatinib et al.) in all cell types tested, such as human epidermoid carcinoma cell line A431 expressing wt EGFR, murine NIH-3T3 cells transfected with wt HER2, as well as breast cancer cell line BT-474 and gastric cancer cell line NCI-N87, which express endogenous HER2. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
HDLM-2	M{XuU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHu2SmZKSzVyPUCuNFA2PzJizszN	MUHTRW5ITVJ?
KASUMI-1	NGnFfXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHvTWM2OD1yLkCwPVEyKM7:TR?=	NXTMcY9FW0GQR1XS
HCC2218	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LJcmlEPTB;MD6wNFk5PyEQvF2=	MVvTRW5ITVJ?
KARPAS-45	NX;vUHlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fmRmlEPTB;MD6wNVY4OSEQvF2=	MX3TRW5ITVJ?
HSC-4	NXHSTplVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{T2eGlEPTB;MD6wNVc1QCEQvF2=	NXvh[WduW0GQR1XS
CHL-1	MoXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzSboRIUUN3ME2wMlAyQDN7IN88US=>	M{LHcHNCVkeHUh?=
KY821	NYPOcpRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\MZWlEPTB;MD6wNlA3KM7:TR?=	NFu0NHJUSU6JRWK=
NCI-N87	NXLrbHJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwMEK3O\|Mh\|ryP	M4LpZXNCVkeHUh?=
DOK	MkPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\yZmlEPTB;MD6wN\|E6PCEQvF2=	NVf6e2NYW0GQR1XS
DSH1	NYTJRYlNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF:3NFVKSzVyPUCuNFM{OTRizszN	M1nrN3NCVkeHUh?=
MDA-MB-175-VII	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGe2SINKSzVyPUCuNFM1OTZizszN	MlXBV2FPT0WU
NCI-H2170	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\LTWM2OD1yLkCzO\|I5KM7:TR?=	NHu3e5BUSU6JRWK=
BT-474	NGrUWXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVP2VVhWUUN3ME2wMlA1QTh4IN88US=>	NVPZRm9XW0GQR1XS
EFO-27	NWDMbJlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTBwMEWxPFIh\|ryP	NVH4VVdyW0GQR1XS
NCI-H720	NXHYbZV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrON3hGUUN3ME2wMlA2OzJ3IN88US=>	NGjmR2NUSU6JRWK=
PC-14	M4DZVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NISxU3ZKSzVyPUCuNFU3PjhizszN	NIPZRZhUSU6JRWK=
EC-GI-10	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUm0bZQ3UUN3ME2wMlA2QTF{IN88US=>	M1vVZXNCVkeHUh?=
KYSE-450	MlLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwMEW5O\|gh\|ryP	NVu4WGtnW0GQR1XS
BPH-1	MkDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;HfGlEPTB;MD6wOVk5QCEQvF2=	NHTQVpBUSU6JRWK=
NCI-H292	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELUbW9KSzVyPUCuNFYxQSEQvF2=	NEHydppUSU6JRWK=
H9	NIj5OnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETBW21KSzVyPUCuNFcyOzJizszN	NWHxfZhDW0GQR1XS
NCI-H526	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnu1TWM2OD1yLkC3PFI{KM7:TR?=	NEfOZodUSU6JRWK=
NCI-H1623	M{jzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnMdo9CUUN3ME2wMlA5ODJ3IN88US=>	MY\TRW5ITVJ?
KYSE-140	NUTlPYg4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfnTWM2OD1yLkC4N\|Mh\|ryP	NH71NI5USU6JRWK=
Ca9-22	M{S5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTBwMEizOVMh\|ryP	MoPlV2FPT0WU
AU565	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTBwMEi1NFQh\|ryP	NVHHXlg2W0GQR1XS
ZR-75-30	M3;DTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfYTWM2OD1yLkC5OVQ2KM7:TR?=	NILRbFNUSU6JRWK=
NCI-H1770	NVe5[2JJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTBwMUCyPEDPxE1?	M2ixTXNCVkeHUh?=
LB2241-RCC	NVLqcI9rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7jeGtKSzVyPUCuNVA5QDRizszN	NWDKVXlEW0GQR1XS
CAL-39	MonqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NViwXYZSUUN3ME2wMlEyPzl{IN88US=>	NHvkRldUSU6JRWK=
UACC-893	M2riTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnVTWM2OD1yLkGxPFg2KM7:TR?=	NGDobVNUSU6JRWK=
LU-65	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3RTIs1UUN3ME2wMlEzPjN\|IN88US=>	MY\TRW5ITVJ?
HN	NFLIXGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XkeWlEPTB;MD6xN\|A4PyEQvF2=	MVjTRW5ITVJ?
TI-73	NW\2XIhFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDOXIJ[UUN3ME2wMlE1PzF3IN88US=>	NEnqRm5USU6JRWK=
KU812	M2r1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jzTmlEPTB;MD6xOVQ2PiEQvF2=	NHLGSGtUSU6JRWK=
SW13	NHHmfFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkD4TWM2OD1yLkG2NlE3KM7:TR?=	Ml;xV2FPT0WU
BB30-HNC	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTBwMU[1O\|Yh\|ryP	M4fOWXNCVkeHUh?=
HSC-2	NHizOohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HxcWlEPTB;MD6xOlg{PyEQvF2=	NGPCOpVUSU6JRWK=
BV-173	MnXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3viOGlEPTB;MD6xO\|U6PiEQvF2=	NEjRZYZUSU6JRWK=
CAL-27	MmCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zafGlEPTB;MD6xO\|Y{PiEQvF2=	MoS0V2FPT0WU
SBC-1	MmnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LtXGlEPTB;MD6xPFk2QSEQvF2=	NWPOUYtFW0GQR1XS
CAL-33	MmXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlWzTWM2OD1yLkKwNVg1KM7:TR?=	MYfTRW5ITVJ?
NCI-H209	NHXGVGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHnTWM2OD1yLkKwOFYh\|ryP	NHLKTlhUSU6JRWK=
COR-L105	M2fhZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkT5TWM2OD1yLkKxNFg1KM7:TR?=	NWXmOoh{W0GQR1XS
HSC-3	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTBwMkGxPVgh\|ryP	M2LhfXNCVkeHUh?=
NCI-H69	Mlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{W3b2lEPTB;MD6yNVQ2OSEQvF2=	M{HMUHNCVkeHUh?=
MOLT-13	MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\hTWM2OD1yLkKzPVc2KM7:TR?=	NUjFN25GW0GQR1XS
ML-2	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\ZTWM2OD1yLkK0PFAzKM7:TR?=	M{HNenNCVkeHUh?=
IGROV-1	MnjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjDTWM2OD1yLkK1PVUzKM7:TR?=	MmXGV2FPT0WU
TK10	M4L3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnmcJRKSzVyPUCuNlY4OzhizszN	M4LJPHNCVkeHUh?=
EoL-1-cell	NGPueYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2Tze2lEPTB;MD6yOlg6OiEQvF2=	MmGxV2FPT0WU
HO-1-N-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTBwMke4OVMh\|ryP	NIDudGhUSU6JRWK=
BHY	MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjQcYZKSzVyPUCuNlg3PTVizszN	NGPVe4ZUSU6JRWK=
LU-139	NWTpVVBXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPh[ZdKSzVyPUCuN\|A2OSEQvF2=	NWrWUldRW0GQR1XS
23132-87	NELQW\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7tTWM2OD1yLkOxPVI{KM7:TR?=	NGHpe5RUSU6JRWK=
ACHN	NELNUHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTBwM{G5PVQh\|ryP	Ml;PV2FPT0WU
DoTc2-4510	NFjiOo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknRTWM2OD1yLkOyNlE6KM7:TR?=	M2PuVXNCVkeHUh?=
BB65-RCC	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTBwM{S1PVMh\|ryP	MV\TRW5ITVJ?
HLE	NX[xO4dlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjrTWM2OD1yLkO1NFQ3KM7:TR?=	MVrTRW5ITVJ?
HCC1419	MmnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTBwM{[0NFgh\|ryP	NVHtZ3Z2W0GQR1XS
A388	MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDOdohtUUN3ME2wMlM3QDV5IN88US=>	MUHTRW5ITVJ?
NUGC-3	NVL1VZBkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TQ[2lEPTB;MD6zPFM4OyEQvF2=	NVf2VI1jW0GQR1XS
KYSE-180	NX;WepNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTBwM{mwPFkh\|ryP	M1jYXHNCVkeHUh?=
TE-6	NGHicJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYm2fI1RUUN3ME2wMlQxOjR4IN88US=>	MVfTRW5ITVJ?
A498	M1vjXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nDcGlEPTB;MD60NFY4PCEQvF2=	NUX5dYZEW0GQR1XS
NCI-H1648	NWLJVJZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmSxTWM2OD1yLkS0NVgzKM7:TR?=	MkC3V2FPT0WU
DU-145	NHLCT\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTBwNES4N\|Mh\|ryP	MWHTRW5ITVJ?
CW-2	MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmW0TWM2OD1yLkS2PVE1KM7:TR?=	NIPFZnFUSU6JRWK=
A431	Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml2yTWM2OD1yLkS4NlM{KM7:TR?=	MnfkV2FPT0WU
SAS	Mn7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTBwNEizPVgh\|ryP	NWnOPXh3W0GQR1XS
NCI-H2126	NWTRbFJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjBRWdKSzVyPUCuOVE6OjZizszN	NGfUZYVUSU6JRWK=
NCI-H358	M{P2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIX5dItKSzVyPUCuOVMzOSEQvF2=	NWfMWmF7W0GQR1XS
FADU	NYe2XJp4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUO5WJZEUUN3ME2wMlU1PDB2IN88US=>	NIG1Z2FUSU6JRWK=
ACN	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwNUWwPVQh\|ryP	MmXEV2FPT0WU
HCC70	M4DG[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPJR\|VoUUN3ME2wMlU4PjZzIN88US=>	M17wfHNCVkeHUh?=
NCI-H1838	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2Ttc2lEPTB;MD62NFI6QSEQvF2=	NHnBXHpUSU6JRWK=
CAL-54	MlXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTBwNkG2NlEh\|ryP	NI\SZYxUSU6JRWK=
NCI-H1975	NXTuZmxKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTBwNkG3Nlgh\|ryP	MofkV2FPT0WU
COR-L88	Mm\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTBwNkSxNVMh\|ryP	M3rsU3NCVkeHUh?=
CTV-1	M4foN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYThc4R2UUN3ME2wMlY1Ozl{IN88US=>	MXXTRW5ITVJ?
EW-18	MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTBwNki2PVgh\|ryP	Mnz5V2FPT0WU
HCC1806	MkL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTBwNkm2OlYh\|ryP	NH24bplUSU6JRWK=
HuP-T4	NY\afoVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXBO45KSzVyPUCuOlk4PiEQvF2=	MoLSV2FPT0WU
MDA-MB-361	NHHOOGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfNclJ[UUN3ME2wMlczPjZ{IN88US=>	NYLkelM3W0GQR1XS
NCI-H1573	NFP2R\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzaTWM2OD1yLkezOlMh\|ryP	M2nsR3NCVkeHUh?=
KU-19-19	NInueopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTBwN{e0OlQh\|ryP	NY\DO5pRW0GQR1XS
COLO-678	NG\B[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rNXGlEPTB;MD64NFg{PCEQvF2=	M4n1OnNCVkeHUh?=
C-33-A	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTBwOEGyPVch\|ryP	NVvMcGViW0GQR1XS
Calu-3	NHnBbY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkT5TWM2OD1yLkixOFM1KM7:TR?=	Mle2V2FPT0WU
AGS	NEDkU\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mon3TWM2OD1yLkizOlQ5KM7:TR?=	NV22VpEyW0GQR1XS
SCC-25	NYrPdG9KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo[3TWM2OD1yLki0NVcyKM7:TR?=	MXLTRW5ITVJ?
JVM-2	Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\ZRYxjUUN3ME2wMlg5Ojl7IN88US=>	NGT3fY5USU6JRWK=
HCE-T	MnPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTBwOEi0Nlgh\|ryP	NYnu[mxIW0GQR1XS
ES4	M2\YVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnaTWM2OD1yLkm3PFM3KM7:TR?=	NF;WO4FUSU6JRWK=
EKVX	NF3uNXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vVXWlEPTB;MT6wNVA3PCEQvF2=	NF\ke2JUSU6JRWK=
D-542MG	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIr1S4pKSzVyPUGuNFExPjRizszN	NHTpTW9USU6JRWK=
SW1116	NWewWIl3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm[2TWM2OD1zLkCxNlg4KM7:TR?=	M4XyZ3NCVkeHUh?=
5637	NITIb3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PBTWlEPTB;MT6wNVUyKM7:TR?=	MYfTRW5ITVJ?
HT-1376	M2PqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETy[INKSzVyPUGuNFE2OTNizszN	M4P2RXNCVkeHUh?=
NB69	NEnEbGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjpV4JuUUN3ME2xMlAzQTR3IN88US=>	NYHlVJVIW0GQR1XS
YKG-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWn2PIJGUUN3ME2xMlA2PDF7IN88US=>	NVe5RndxW0GQR1XS
EW-3	NIXremFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTFwMEe4PFMh\|ryP	NHPId3JUSU6JRWK=
GCIY	MoDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTFwMEixNFQh\|ryP	NH;ic\|JUSU6JRWK=
SK-MES-1	NHP5SWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DzV2lEPTB;MT6xNVQ5PyEQvF2=	NWK5SmlbW0GQR1XS
PANC-08-13	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTkPXNKSzVyPUGuNVY1OTZizszN	NVnXe\|lqW0GQR1XS
SK-NEP-1	MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{Tjb2lEPTB;MT6xO\|UyOyEQvF2=	NWXLT3p1W0GQR1XS
SW954	Mnn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFezfGtKSzVyPUGuNlAzOTRizszN	NUTVXohVW0GQR1XS
NCI-SNU-5	NFHab4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvFTWM2OD1zLkKzPUDPxE1?	NUjOcYliW0GQR1XS
SW48	M2rIfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWW0WopOUUN3ME2xMlI2PDN{IN88US=>	Mlr4V2FPT0WU
HT-3	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\WTWM2OD1zLkK4O\|U{KM7:TR?=	NYD0PIxNW0GQR1XS
ETK-1	MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnRS2VEUUN3ME2xMlM4PDV4IN88US=>	NH3TcmRUSU6JRWK=
SCC-15	MoToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlm4TWM2OD1zLkO5OFUyKM7:TR?=	MVHTRW5ITVJ?
DU-4475	NISxdopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfkXWJkUUN3ME2xMlQxOTJzIN88US=>	NIDqSZJUSU6JRWK=
NB5	NV[5fIdDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXpTWM2OD1zLkSxN\|E4KM7:TR?=	MUXTRW5ITVJ?
CFPAC-1	NY\lV4lGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTFwNEK0PVMh\|ryP	MmnHV2FPT0WU
NCI-H630	NYX6endxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDTTWM2OD1zLkS1OVgzKM7:TR?=	MkjpV2FPT0WU
NCI-H82	M3XCRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3OeXVKSzVyPUGuOVQxODZizszN	Mo\GV2FPT0WU
ECC10	M4\4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDPVnZKSzVyPUGuOVU{PjlizszN	M336fHNCVkeHUh?=
K5	M3XnTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrYN4sxUUN3ME2xMlU5OzV5IN88US=>	M1j1OHNCVkeHUh?=
ME-180	NIPaeG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjMclNKSzVyPUGuOlExQTZizszN	MVPTRW5ITVJ?
KYSE-410	NWHWVmd2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTFwNkW2O\|Ih\|ryP	M3rJRnNCVkeHUh?=
G-401	M{LFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\hTWM2OD1zLk[3OFE{KM7:TR?=	MXjTRW5ITVJ?
TGBC24TKB	MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4CxWWlEPTB;MT62PFI{KM7:TR?=	NXHvTlNzW0GQR1XS
Detroit562	NEHXOVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PkfGlEPTB;MT63NFE2OiEQvF2=	NV3iPWptW0GQR1XS
OE19	M{PxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTFwN{G1NVIh\|ryP	NHPIN4VUSU6JRWK=
CAKI-1	NHTUVIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPWTWM2OD1zLke4NlEyKM7:TR?=	MV7TRW5ITVJ?
TE-12	NEmzOFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrnR\|lrUUN3ME2xMlgxPDF2IN88US=>	MXvTRW5ITVJ?
NCI-H1666	NXPpdXpZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLZTWM2OD1zLkiwPVQ5KM7:TR?=	M1LOd3NCVkeHUh?=
TE-1	NEnHV\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7FTWM2OD1zLkixOFc2KM7:TR?=	MYTTRW5ITVJ?
CAL-12T	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTFwOEi5OFUh\|ryP	M1rkdXNCVkeHUh?=
TE-8	NXrWcYtET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33w[2lEPTB;MT65NVM4PyEQvF2=	MnjyV2FPT0WU
KYSE-270	NVm4fWt7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTJwMEK3N\|Ih\|ryP	MXLTRW5ITVJ?
GMS-10	NEP0Z5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TKSWlEPTB;Mj6wN\|UyPyEQvF2=	M3X1THNCVkeHUh?=
A2780	M{DtZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmi3TWM2OD1{LkC2Nlk1KM7:TR?=	M2HSfnNCVkeHUh?=
OMC-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTJwMEixOlkh\|ryP	M3nOZnNCVkeHUh?=
LoVo	NHSzS4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1:xbmlEPTB;Mj6xNFc6PyEQvF2=	NVTEcGl4W0GQR1XS
PANC-03-27	Mo\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXTTWM2OD1{LkG2OlMyKM7:TR?=	NGXnfHhUSU6JRWK=
MDA-MB-157	NIX3dZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn31TWM2OD1{LkKxPFI5KM7:TR?=	NI\0e3ZUSU6JRWK=
CaR-1	MlzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TuOGlEPTB;Mj6yPFI5OSEQvF2=	Mk\EV2FPT0WU
769-P	MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\KWGlEPTB;Mj6yPVA{PyEQvF2=	NH7x[4FUSU6JRWK=
NB7	NGHN[29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXpOIpKSzVyPUKuNlk3PzZizszN	MULTRW5ITVJ?
MKN7	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTJwM{WzN\|Uh\|ryP	MVjTRW5ITVJ?
NCI-H1048	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkOyTWM2OD1{LkS5NVU5KM7:TR?=	MX7TRW5ITVJ?
RCM-1	M3G3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTJwNUK5N\|gh\|ryP	NHX3fJhUSU6JRWK=
HT55	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUH4V4l6UUN3ME2yMlU4OzhizszN	NFuzRoZUSU6JRWK=
HCC1569	M3zNUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1e0Z2lEPTB;Mj61PFI6PyEQvF2=	M4PTfXNCVkeHUh?=
LXF-289	MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlr0TWM2OD1{Lk[zOVY2KM7:TR?=	NGC1epBUSU6JRWK=
OVCAR-3	M2TLTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHrS4VKSzVyPUKuOlcyPjdizszN	Mnz0V2FPT0WU
TE-10	NFy4OpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTJwNkiwO\|gh\|ryP	NV7X[WM5W0GQR1XS
SNU-C2B	NYXjVWoxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\oOWlEPTB;Mj62PFYyPiEQvF2=	MlznV2FPT0WU
LB1047-RCC	NFHYVmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\tTWM2OD1{Lke0PFg5KM7:TR?=	NEey[YxUSU6JRWK=
SN12C	M1T4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\2N29kUUN3ME2yMlkyQTZ2IN88US=>	MmPvV2FPT0WU
786-0	NWjpT5lsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDTPXRKSzVyPUOuNFY1ODhizszN	MX\TRW5ITVJ?
HT-29	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVzvU2hMUUN3ME2zMlA4OzB7IN88US=>	NGjwZ4FUSU6JRWK=
RPMI-7951	M{nUcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTNwMEe1PUDPxE1?	MUHTRW5ITVJ?
NBsusSR	MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTNwMUiyOVQh\|ryP	MWDTRW5ITVJ?
NKM-1	M{Lz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTNwMUi3OFQh\|ryP	NVzrcINIW0GQR1XS
Capan-2	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnXNmJoUUN3ME2zMlQ3QDd3IN88US=>	NFzzfo9USU6JRWK=
MKN1	M3zwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXEWogxUUN3ME2zMlQ4OTB6IN88US=>	NFfMV4lUSU6JRWK=
OAW-42	NI\lT5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIKxfWdKSzVyPUOuOVAxOjZizszN	MXPTRW5ITVJ?
SKG-IIIa	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFqzZXdKSzVyPUOuOVIzOzdizszN	MkTmV2FPT0WU
no-11	MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnIUGZtUUN3ME2zMlU{PTZ2IN88US=>	MYTTRW5ITVJ?
NY	M1rlVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlXYTWM2OD1\|LkWzOlU2KM7:TR?=	NHfCWXlUSU6JRWK=
HEC-1	NX;rS4M1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXJO5ZlUUN3ME2zMlU5QTVizszN	NFLwV2dUSU6JRWK=
NCI-H441	M1vYWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mom5TWM2OD1\|LkW5PFQyKM7:TR?=	NHf1S3BUSU6JRWK=
NCI-H2009	NHLleYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrlTWM2OD1\|Lk[xNlE3KM7:TR?=	MYXTRW5ITVJ?
T47D	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTNwNkKyNVch\|ryP	MoXFV2FPT0WU
SNU-449	NWj2RnloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HzUGlEPTB;Mz62OVgzPiEQvF2=	MXPTRW5ITVJ?
NCI-SNU-1	MkfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTNwNkm3N\|Uh\|ryP	M2jteXNCVkeHUh?=
BT-20	M3\Ve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTNwNkm3PVUh\|ryP	MYHTRW5ITVJ?
LS-123	NVjJbmRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1P2ZmlEPTB;Mz63OFI5PCEQvF2=	NYG4RYpQW0GQR1XS
8305C	NXPBenVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzUTnpKSzVyPUOuO\|U6OTFizszN	M1ntZnNCVkeHUh?=
OCUB-M	M3v5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTNwN{[xPFch\|ryP	NIDHd\|lUSU6JRWK=
KOSC-2	NFvFTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XJc2lEPTB;Mz64N\|Q2OSEQvF2=	M{WzPXNCVkeHUh?=
NCI-H1693	Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDjZ3JKSzVyPUOuPFQyQDFizszN	NWXJUYhlW0GQR1XS
TE-9	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoW0TWM2OD1\|Lki0N\|gzKM7:TR?=	MUPTRW5ITVJ?
MV-4-11	M2C2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvOTWM2OD1\|Lki3PVk1KM7:TR?=	MWLTRW5ITVJ?
GAMG	NGPRSldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmT4TWM2OD1\|LkmxN\|E1KM7:TR?=	MWHTRW5ITVJ?
KNS-62	M33heGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGf0cZhKSzVyPUOuPVQ4OzFizszN	Mnm1V2FPT0WU
MC116	MmnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\vcpVKSzVyPUOuPVU1QDlizszN	NV;iOZV2W0GQR1XS
647-V	NH65dlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfsTWM2OD1\|Lkm4OFUzKM7:TR?=	MULTRW5ITVJ?
U-87-MG	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEGzT4hKSzVyPUSuNVA1QDFizszN	NETpVZJUSU6JRWK=
RPMI-8226	MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TP[WlEPTB;ND6xNVY{OSEQvF2=	NYPrWoNqW0GQR1XS
SW1417	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLnWWZuUUN3ME20MlEzOTR5IN88US=>	NYjxN5dqW0GQR1XS
LAMA-84	M3\6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPvPFljUUN3ME20MlE4ODJizszN	MnH3V2FPT0WU
LS-513	M1rtSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLVTWM2OD12LkOxNlE4KM7:TR?=	NF3HVHlUSU6JRWK=
KLE	MlrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\QZ25KSzVyPUSuOFA5OTlizszN	NV;BTYJzW0GQR1XS
HCT-116	NEH1XWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTRwNEGwNFch\|ryP	NXzkOVdKW0GQR1XS
EPLC-272H	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\5O5hSUUN3ME20MlQyPTN\|IN88US=>	NHv2RmNUSU6JRWK=
KS-1	NVyz[ldnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LVXGlEPTB;ND61NFg5QSEQvF2=	MnjTV2FPT0WU
HT-1197	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHqNndjUUN3ME20MlUzPjZ7IN88US=>	NGG2fm1USU6JRWK=
LCLC-97TM1	M3WzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3ueohnUUN3ME20MlU{Pjh4IN88US=>	MV3TRW5ITVJ?
ES5	Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTRwOEO3NlMh\|ryP	MXjTRW5ITVJ?
CTB-1	NF\JTJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFe2PG9KSzVyPUSuPFQ5QCEQvF2=	NHe2ZVlUSU6JRWK=
HL-60	NWjHclc4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEG3TmJKSzVyPUSuPFY3OTFizszN	NXywNZZCW0GQR1XS
VM-CUB-1	M2DmNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXCZ\|JjUUN3ME20Mlg3QDF7IN88US=>	NEXIXYRUSU6JRWK=
MEG-01	Mn7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17JVmlEPTB;ND65PVQxOyEQvF2=	M4KwZnNCVkeHUh?=
KYSE-520	NVzGcJhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrZdY9KUUN3ME21MlIxQDN7IN88US=>	MlHMV2FPT0WU
HuO-3N1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vXcGlEPTB;NT6yOFA1OyEQvF2=	NUDnZ\|c3W0GQR1XS
SW620	M2fpOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX60PHl6UUN3ME21MlI1QTZ2IN88US=>	MnLxV2FPT0WU
U031	NGTZXYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Dx[mlEPTB;NT6yOVQzPCEQvF2=	NF[0S2RUSU6JRWK=
TE-5	M33j[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTVwNEC4OUDPxE1?	NE\6NmZUSU6JRWK=
NCI-H747	M13Rcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;sTWM2OD13LkSyOFczKM7:TR?=	NUC1clFIW0GQR1XS
MG-63	MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TqbmlEPTB;NT60PFc3OiEQvF2=	MYfTRW5ITVJ?
HC-1	NWrSTHNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTVwNUG4N\|kh\|ryP	M3\0THNCVkeHUh?=
HCC2998	NHrrPYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnThTWM2OD13LkWyOlE2KM7:TR?=	MkXmV2FPT0WU
NTERA-S-cl-D1	NV3kV4M5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{Oxb2lEPTB;NT61OFU{PyEQvF2=	M2rlPXNCVkeHUh?=
KINGS-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLjXpRKSzVyPUWuOlA6PDRizszN	NX;YdohQW0GQR1XS
D-423MG	NFqzXG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\0U2lEPTB;NT62NVcxPSEQvF2=	M{X4W3NCVkeHUh?=
SW962	MoPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHS5eHBKSzVyPUWuOlIxOzJizszN	MoDZV2FPT0WU
LOXIMVI	MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWW2dW9HUUN3ME21MlY{QDd\|IN88US=>	MWLTRW5ITVJ?
LS-411N	M17GfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk[xTWM2OD13Lke5OFQyKM7:TR?=	NV;DO3dSW0GQR1XS
NCI-H2291	NF\wWXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnK[YRKSzVyPUWuPVg6PDNizszN	MnuwV2FPT0WU
A549	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTZwMUK1OVMh\|ryP	NGrpeZVUSU6JRWK=
LS-1034	NHHxXFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjt[WJKSzVyPU[uNlA4ODZizszN	M2HCbXNCVkeHUh?=
NB14	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXifJFKSzVyPU[uOFM5OzZizszN	MmnPV2FPT0WU
NCI-H1299	M1i3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEmwSIZKSzVyPU[uOlMyPzFizszN	MkfaV2FPT0WU
BT-549	NVjRSZhrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfaS5JsUUN3ME22MlY3QDh7IN88US=>	NXi4V2xyW0GQR1XS
J-RT3-T3-5	M2DpWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTZwOE[5JO69VQ>?	MoHQV2FPT0WU
SW756	NV\SWHhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTZwOUGxO\|Yh\|ryP	NGPvNHlUSU6JRWK=
DJM-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnKzTWM2OD14LkmyNFEzKM7:TR?=	MnLBV2FPT0WU
GP5d	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTrTWM2OD14Lkm3N\|k1KM7:TR?=	NGfGR4FUSU6JRWK=
MOLT-4	NV7DOFVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rrVmlEPTB;Nz6wNlE{PSEQvF2=	M3jrfnNCVkeHUh?=
NCI-H28	NFzicmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHjdnVKSzVyPUeuNVY1ODVizszN	M3fXTnNCVkeHUh?=
MN-60	M1XjdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTdwMkiwPFkh\|ryP	M1rVOXNCVkeHUh?=
RMG-I	NGj5dZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3TFeGlEPTB;Nz6zPVI6PiEQvF2=	NVnMOlkzW0GQR1XS
COLO-800	NHT5TXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTdwNEG0OFYh\|ryP	MU\TRW5ITVJ?
DB	NI[2XWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7MTWM2OD15Lk[xNFA2KM7:TR?=	M2H4WnNCVkeHUh?=
Ca-Ski	MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrSTWttUUN3ME23MlY1OjV7IN88US=>	M1nEOnNCVkeHUh?=
HEL	M3rLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEX6OoVKSzVyPUeuO\|EzODNizszN	MoP3V2FPT0WU
NH-12	NVKwdXVqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXSZVBwUUN3ME23MlczQDB6IN88US=>	NWXFO3piW0GQR1XS
LB373-MEL-D	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;mTWM2OD15Lke2O\|cyKM7:TR?=	MXvTRW5ITVJ?
SW900	MonLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnRS4VKSzVyPUeuPFIyOjFizszN	M{LUcnNCVkeHUh?=
JVM-3	NHzqfVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;COYxTUUN3ME23Mlg6PTl7IN88US=>	NVjLZYlkW0GQR1XS
OAW-28	NIXUTG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLxcXpKSzVyPUeuPVQ2PzhizszN	MljyV2FPT0WU
KURAMOCHI	NHPFS5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jTWmlEPTB;Nz65OFgyOSEQvF2=	MXrTRW5ITVJ?
BE-13	NUfkeZFjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXvTINoUUN3ME23Mlk5OTF{IN88US=>	Ml;FV2FPT0WU
VMRC-RCZ	NH61WmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRThwMEG2PVch\|ryP	MYHTRW5ITVJ?
NCI-H727	M3KwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NET4eY5KSzVyPUiuNVA1OiEQvF2=	NWnYfphxW0GQR1XS
SW1710	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DXSmlEPTB;OD6xPFUyPSEQvF2=	MorxV2FPT0WU
D-502MG	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4fqN2lEPTB;OD6yPVI5OiEQvF2=	MXrTRW5ITVJ?
NCI-H1993	MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLsTWM2OD16LkOzOlMyKM7:TR?=	MV7TRW5ITVJ?
SCC-4	Mn3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorhTWM2OD16LkS0NFU6KM7:TR?=	MWfTRW5ITVJ?
HAL-01	NHHyb5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mln6TWM2OD16LkWxPVEh\|ryP	MkT1V2FPT0WU
GT3TKB	NXLVVW92T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LuZWlEPTB;OD62O\|k3PCEQvF2=	M{TIenNCVkeHUh?=
SK-OV-3	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHiV21KSzVyPUiuO\|E{OjlizszN	MWTTRW5ITVJ?
COLO-829	NI\zVo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fwS2lEPTB;OD64NFk4PiEQvF2=	NHzT[FhUSU6JRWK=
OCI-AML2	NVK0[YE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnYTWM2OD16Lkm1OFgyKM7:TR?=	M37vU3NCVkeHUh?=
OS-RC-2	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jrTGlEPTB;OT6wNlE6KM7:TR?=	Mm\CV2FPT0WU
BFTC-909	M2DWbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HwdmlEPTB;OT6wOlc6QSEQvF2=	MXTTRW5ITVJ?
EW-11	NEjFR\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYW2fpdHUUN3ME25MlE4PjV\|IN88US=>	NGnLRYRUSU6JRWK=
HCE-4	NWTO[opsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrkNIpKSzVyPUmuNlE2PThizszN	NHLDfopUSU6JRWK=
BALL-1	NVy2dI5vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPaTWM2OD17LkKxPVA4KM7:TR?=	NHLSTmRUSU6JRWK=
SF539	NH\xcGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3:4VGlEPTB;OT6yN\|U3OiEQvF2=	MYHTRW5ITVJ?
CAMA-1	MoPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3[1W2lEPTB;OT6yPFEzQCEQvF2=	M4nZSXNCVkeHUh?=
C32	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTlwM{OwOlQh\|ryP	M1LLTHNCVkeHUh?=
NCI-H1703	NHv1OFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rGV2lEPTB;OT6zOFM4PSEQvF2=	Mn\CV2FPT0WU
NCI-H1650	NVi3PJgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLZ[Y5KSzVyPUmuOlA6PDZizszN	M17nfnNCVkeHUh?=
NCI-H1563	NXrzPYlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUT5c\|dQUUN3ME25Mlc3ODNzIN88US=>	MWTTRW5ITVJ?
CAL-85-1	NHXrXGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTlwOEezPFMh\|ryP	NVnVc2xrW0GQR1XS
UM-UC-3	MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13xVGlEPTB;OT65OVA{KM7:TR?=	M2HDd3NCVkeHUh?=
BxPC-3	NF\1OnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPmVYJIUUN3ME2xNE4xQTd{IN88US=>	Ml3RV2FPT0WU
MHH-PREB-1	NGHDRZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUD3b4tmUUN3ME2xNE4yQTl7IN88US=>	NXGxeG15W0GQR1XS
DEL	NInoNYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTFyLkO5OFYh\|ryP	M1jtZ3NCVkeHUh?=
HuCCT1	Ml7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\XbGlEPTB;MUCuOlA{OyEQvF2=	NWDVfpVIW0GQR1XS
OVCAR-4	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTFyLki4N\|Uh\|ryP	NV;ZcVNVW0GQR1XS
CAL-72	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zqSGlEPTB;MUCuPVM6OSEQvF2=	M{W0bXNCVkeHUh?=
HCC1954	Ml3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmC3TWM2OD1zMT6wO\|U1KM7:TR?=	NVe0ZVZCW0GQR1XS
EFO-21	NHLIUYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;udoVWUUN3ME2xNU4yODR3IN88US=>	MV3TRW5ITVJ?
FTC-133	Mn\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTFzLkG0NFch\|ryP	MoTHV2FPT0WU
SK-MEL-24	MorlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2ftS2lEPTB;MUGuNlM3PiEQvF2=	MmHSV2FPT0WU
UACC-62	NFS4NXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXEOphKSzVyPUGxMlI{PjhizszN	MmDKV2FPT0WU
NCI-H650	Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfyW4dKSzVyPUGxMlI1OThizszN	M1H2enNCVkeHUh?=
ALL-PO	MnXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlTlTWM2OD1zMT6yOVEzKM7:TR?=	MoHtV2FPT0WU
T84	NFHoXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTFzLkO5NFch\|ryP	NGDwUmNUSU6JRWK=
IST-MEL1	MkHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LhXWlEPTB;MUGuOFU2QSEQvF2=	NYnFTVhrW0GQR1XS
SW626	NVvU[FA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTFzLkW3OVUh\|ryP	NVv0ZYRmW0GQR1XS
RPMI-2650	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnodox7UUN3ME2xNU42QDh3IN88US=>	MoD6V2FPT0WU
MC-IXC	Ml;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjCN\|RKSzVyPUGxMlY4OjhizszN	M3nTbnNCVkeHUh?=
HOP-62	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DLemlEPTB;MUGuOlc3PCEQvF2=	Mm\VV2FPT0WU
NOS-1	NGL1eYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjLVpdKSzVyPUGxMlcyODlizszN	Mo\LV2FPT0WU
SW1573	MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnsR\|FKSzVyPUGxMlczQTVizszN	NEDmUWlUSU6JRWK=
WM-115	M1S1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTFzLke1PFgh\|ryP	MX3TRW5ITVJ?
HuO9	NGnvd4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTFzLki3O\|Qh\|ryP	NEPmRnJUSU6JRWK=
YAPC	M{mwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTFzLkmyOVkh\|ryP	NWDjO2o4W0GQR1XS
MDA-MB-453	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{GxRmlEPTB;MUGuPVUyPSEQvF2=	MlnwV2FPT0WU
NCI-H596	M{HHb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWG1O\|JiUUN3ME2xNk4xOzZ7IN88US=>	MkXxV2FPT0WU
A172	MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4GwPGlEPTB;MUKuNFc6QCEQvF2=	NILDc2xUSU6JRWK=
RS4-11	NFjPSpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnrZYhzUUN3ME2xNk4yPzJ3IN88US=>	MY\TRW5ITVJ?
HCC1937	NVvOUJlRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rDOmlEPTB;MUKuO\|U3PCEQvF2=	M{WwT3NCVkeHUh?=
SW837	M1zVd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HD[2lEPTB;MUKuPVAzQCEQvF2=	MUDTRW5ITVJ?
NMC-G1	NIDOOnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXtTWM2OD1zMj65NlM1KM7:TR?=	NWK0ZoJqW0GQR1XS
PFSK-1	M3Xycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIKyZWtKSzVyPUGzMlA3KM7:TR?=	NXTSW2prW0GQR1XS
DBTRG-05MG	M2LLRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nSRmlEPTB;MUOuNFY{OiEQvF2=	MoPMV2FPT0WU
SK-UT-1	NYfQSlB5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTF\|LkGwPFMh\|ryP	NE\zXXhUSU6JRWK=
OVCAR-5	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\vTndLUUN3ME2xN{4yPTl\|IN88US=>	NEjX[lhUSU6JRWK=
8505C	NG\zS\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTF\|LkKwOlch\|ryP	NFvqOIFUSU6JRWK=
SK-MEL-1	NVjk[mQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXQPXRKSzVyPUGzMlcyOzVizszN	MYrTRW5ITVJ?
LK-2	MofWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPJNmVsUUN3ME2xN{44PjN7IN88US=>	M3XPcHNCVkeHUh?=
OE33	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnpUGtKSzVyPUGzMlc5PiEQvF2=	NGLzXGRUSU6JRWK=
Ramos-2G6-4C10	MoDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\zfWlEPTB;MUSuNFIxOiEQvF2=	M{DURXNCVkeHUh?=
EW-13	Mm\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\UcGlEPTB;MUSuNFM2OiEQvF2=	M2LodHNCVkeHUh?=
NCI-H1793	M1PWSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYr2TnozUUN3ME2xOE4zODh5IN88US=>	M4fIN3NCVkeHUh?=
BHT-101	MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHGxcXdKSzVyPUG0MlI1OSEQvF2=	Mo\QV2FPT0WU
RKO	MmnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1HiOmlEPTB;MUSuOVA4PSEQvF2=	MmHWV2FPT0WU
NEC8	M2fYPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPobYFKSzVyPUG0MlU1PzJizszN	NULtdWt1W0GQR1XS
PANC-10-05	NUnnTIRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zzeWlEPTB;MUSuOlI1PyEQvF2=	M1PRcHNCVkeHUh?=
NCI-H2030	MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPnTWM2OD1zND62OFQ5KM7:TR?=	MXPTRW5ITVJ?
C2BBe1	Ml2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnBTWM2OD1zND63OlQh\|ryP	NGfxNm5USU6JRWK=
EM-2	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWO1RXZTUUN3ME2xOE45PTd4IN88US=>	MXTTRW5ITVJ?
HCC1395	NYLpfot7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjiZVlKSzVyPUG0Mlk{OzhizszN	MY\TRW5ITVJ?
A2058	NHfHZVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTF3LkC0NFkh\|ryP	M2XPWXNCVkeHUh?=
SW1463	NWTYd3g5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTF3LkC0PFUh\|ryP	M3OwV3NCVkeHUh?=
J82	MoDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1K0WmlEPTB;MUWuNFU4KM7:TR?=	MmTGV2FPT0WU
CAL-120	NGHqeIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnx[4tKSzVyPUG1MlE1PDdizszN	NV7mN4IyW0GQR1XS
COLO-824	M3fsbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2naRmlEPTB;MUWuNVU4QSEQvF2=	Mke1V2FPT0WU
LNCaP-Clone-FGC	NUP1fo4xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTF3LkSyOFgh\|ryP	NYXobm1HW0GQR1XS
CP66-MEL	Mn7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTF3LkS2PFgh\|ryP	Ml\aV2FPT0WU
OC-314	M3nUeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULPUWF5UUN3ME2xOU41PzF2IN88US=>	MlX2V2FPT0WU
OVCAR-8	Mnf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTF3Lki4OlEh\|ryP	NGLJPHZUSU6JRWK=
MFE-280	M1jZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\4OmlEPTB;MU[uNFQ5QCEQvF2=	NH34UFhUSU6JRWK=
MHH-NB-11	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTF4LkC4N\|kh\|ryP	NX7KOGs5W0GQR1XS
SW1990	NYnOc2JGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUO5SFF1UUN3ME2xOk4yPzV3IN88US=>	M1;NWHNCVkeHUh?=
U-266	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fUdWlEPTB;MU[uNlI6QSEQvF2=	Mm\TV2FPT0WU
MFM-223	MkjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\PVYM2UUN3ME2xOk4{QTZ3IN88US=>	NWnYc5V1W0GQR1XS
L-363	NHL0WHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\CXGlEPTB;MU[uOFU4PyEQvF2=	Ml7rV2FPT0WU
MCF7	NX3LUJhVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjZTWM2OD1zNj60O\|I{KM7:TR?=	MX7TRW5ITVJ?
SK-MEL-3	NHz3OYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2ThfWlEPTB;MU[uOFc5PyEQvF2=	NWPZbGd3W0GQR1XS
HH	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGD4botKSzVyPUG2MlUyPjJizszN	MmrsV2FPT0WU
no-10	M1yz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXOTWM2OD1zNj62N\|Q{KM7:TR?=	NInLcHJUSU6JRWK=
HuP-T3	MmHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jUemlEPTB;MU[uOlU4PiEQvF2=	Ml;OV2FPT0WU
QIMR-WIL	NWXCZVJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTF4LkexNFUh\|ryP	M{PTO3NCVkeHUh?=
NCI-H1092	M3nuNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrTS2JKSzVyPUG2Mlg{OTZizszN	NYXNVZR2W0GQR1XS
MZ2-MEL	NIHN[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTF4Lki0NFMh\|ryP	NGjrRnhUSU6JRWK=
ES3	MmLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELDbGpKSzVyPUG2MlkyOzRizszN	NV2xSZd4W0GQR1XS
COLO-684	M3nOR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTF4Lkm0O\|ch\|ryP	M1q0eXNCVkeHUh?=
NCI-H661	NFTiUXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7ocFFrUUN3ME2xOk46Pjl2IN88US=>	NVXlR\|I2W0GQR1XS
CP50-MEL-B	Mly1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTF5LkCzOFMh\|ryP	MXjTRW5ITVJ?
NCI-H2405	MknuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3n0W2lEPTB;MUeuNVk4PCEQvF2=	NEDme4RUSU6JRWK=
U-2-OS	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fVbWlEPTB;MUeuOVMxPyEQvF2=	NV3xcoFVW0GQR1XS
RERF-LC-MS	MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTF5LkW1NFgh\|ryP	NGPGVZpUSU6JRWK=
NCI-H2342	NXvH[WpTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPGTWM2OD1zNz61OVch\|ryP	MWTTRW5ITVJ?
ES8	NGDtSZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVT6SGNbUUN3ME2xO{43ODh5IN88US=>	NUC0S4JsW0GQR1XS
MOLT-16	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTF5Lki5N\|Qh\|ryP	MUPTRW5ITVJ?
RH-18	MnuxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7zTWM2OD1zOD6wNFM2KM7:TR?=	M4fqPXNCVkeHUh?=
D-283MED	NXHQd3BHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzlXFhKSzVyPUG4MlAxQDhizszN	MVjTRW5ITVJ?
RCC10RGB	MofYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfJZpNFUUN3ME2xPE4xPTV7IN88US=>	NF7PT4lUSU6JRWK=
NCI-H1437	M2WzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH\3bYRKSzVyPUG4MlE3PDFizszN	MWXTRW5ITVJ?
SW982	NFLzV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFi4eWdKSzVyPUG4MlI3PzFizszN	MXzTRW5ITVJ?
IST-MES1	NIfvSJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnqV4xKSzVyPUG4MlQ1OjhizszN	NU\XVpMzW0GQR1XS
A704	NXPnSpJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkP5TWM2OD1zOD60O\|U{KM7:TR?=	NWTRZYpMW0GQR1XS
ESS-1	NX7GS4d2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTF6LkWyNFUh\|ryP	MkjsV2FPT0WU
SCH	Mn3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;HTWM2OD1zOD62OFU3KM7:TR?=	Ml:4V2FPT0WU
COLO-320-HSR	NVrWZZZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfNZmRKSzVyPUG4Mlc1PiEQvF2=	NXXNfpJ{W0GQR1XS
Mo-T	M3\RW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmThTWM2OD1zOD64NlA1KM7:TR?=	M2HCSHNCVkeHUh?=
Saos-2	MkDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWP0OotDUUN3ME2xPU4yOTZ{IN88US=>	M4\nfHNCVkeHUh?=
SW684	M3vrSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\vSGlEPTB;MUmuNVMzPiEQvF2=	NYn2fIhNW0GQR1XS
KMOE-2	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PBNmlEPTB;MUmuNlI1OiEQvF2=	MlPXV2FPT0WU
MMAC-SF	NYjzeJQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHLTWM2OD1zOT6yOlA4KM7:TR?=	M3\HO3NCVkeHUh?=
JAR	MmfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DPV2lEPTB;MUmuNlk6KM7:TR?=	NVfadJBPW0GQR1XS
SK-MEL-28	NHLBdmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nuUWlEPTB;MUmuN\|M3OyEQvF2=	MV3TRW5ITVJ?
KNS-81-FD	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTF7LkW0Olgh\|ryP	NFXhfGFUSU6JRWK=
ES7	NGC0[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTF7Lk[yPVIh\|ryP	M3rieXNCVkeHUh?=
AsPC-1	NYjvUnc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfw[ZFKSzVyPUG5MlY1PzFizszN	M{TjfnNCVkeHUh?=
NCI-H1155	NIHDdHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LtTGlEPTB;MUmuO\|I{QCEQvF2=	MVHTRW5ITVJ?
KYSE-510	MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDCO2s6UUN3ME2xPU45PzR6IN88US=>	M3O2RnNCVkeHUh?=
ES1	NF7WSFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NID2fWFKSzVyPUG5MlkzOTNizszN	MXPTRW5ITVJ?
PC-3	MlrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTF7Lkm2NFQh\|ryP	M1;rR3NCVkeHUh?=
GCT	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn20TWM2OD1{MD6zNFI3KM7:TR?=	Mn;UV2FPT0WU
KARPAS-299	NVrafVdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEj4U5BKSzVyPUKwMlM1OjJizszN	M17xWXNCVkeHUh?=
DOHH-2	MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnCOmdIUUN3ME2yNE42PDZ\|IN88US=>	MljZV2FPT0WU
COLO-741	Mki2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTJyLk[2JO69VQ>?	MVzTRW5ITVJ?
NCI-H1395	NEnU[\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTJyLk[2PVch\|ryP	M3HhbnNCVkeHUh?=
HCC1187	MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLwRWFKSzVyPUKwMlY4OzRizszN	NEiyVmdUSU6JRWK=
Becker	Ml;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPMOll7UUN3ME2yNE44OjBzIN88US=>	NVvSd4hQW0GQR1XS
LU-134-A	M2T3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrqSVFwUUN3ME2yNU4yODJ4IN88US=>	M2XVdXNCVkeHUh?=
MKN45	NIrqOGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTJzLkG1OVEh\|ryP	MoLpV2FPT0WU
LC-2-ad	NUjZUGtXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTJzLkK3Nlkh\|ryP	MVHTRW5ITVJ?
EW-24	M1;BbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDmXFBKSzVyPUKxMlM6PDVizszN	NFvKSpJUSU6JRWK=
SK-N-AS	NWPCVVZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGniTItKSzVyPUKxMlgzPzZizszN	MlX0V2FPT0WU
NCI-H2052	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7LTWM2OD1{MT64PVY{KM7:TR?=	NWrVPIFMW0GQR1XS
A4-Fuk	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGiwXGtKSzVyPUKyMlE1OTlizszN	NVPYdGpwW0GQR1XS
NB10	NVroXHIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPUNnNKSzVyPUKyMlI{PzFizszN	NVTFbGNmW0GQR1XS
CHP-212	MnXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DtO2lEPTB;MkKuN\|IzOiEQvF2=	NUnoRZI6W0GQR1XS
KM12	MkLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zPOWlEPTB;MkKuN\|U3KM7:TR?=	Mne3V2FPT0WU
JEG-3	NVq1eG8zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTJ{LkO3PEDPxE1?	MnXwV2FPT0WU
LN-405	NICzXnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTJ{LkW5NVMh\|ryP	NWDGcop2W0GQR1XS
HCT-15	NWDTcmp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTJ{Lke0OFEh\|ryP	NFLu[JhUSU6JRWK=
MLMA	NWfrOXp6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHDWHdKSzVyPUKyMlc1PyEQvF2=	NHHGNFZUSU6JRWK=
GI-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzjTWM2OD1{Mj63OlU5KM7:TR?=	M4Pp[HNCVkeHUh?=
RT-112	M1fTTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTMOHBYUUN3ME2yNk45PjF4IN88US=>	NUjvPWo5W0GQR1XS
MPP-89	MoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LtWGlEPTB;MkKuPFY3OSEQvF2=	NYjzdoRlW0GQR1XS
A3-KAW	M4HEW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXiOZlIUUN3ME2yN{4yODB\|IN88US=>	NVzxbJJ6W0GQR1XS
KALS-1	MoG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XYSmlEPTB;MkOuNVQyPCEQvF2=	Mn\jV2FPT0WU
SF126	NX\vOZVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXflU4tTUUN3ME2yN{43QTJ2IN88US=>	NIOzUZNUSU6JRWK=
SiHa	NVPEcmdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXz5N2VJUUN3ME2yN{46OzJ5IN88US=>	NHPobVBUSU6JRWK=
MDA-MB-415	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELadnRKSzVyPUKzMlk1QTlizszN	NYnseZl4W0GQR1XS
Daoy	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTJ2LkGyOkDPxE1?	Moq0V2FPT0WU
COR-L23	M4THN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M365U2lEPTB;MkSuNVc3PyEQvF2=	M4LnWXNCVkeHUh?=
KG-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7wTWM2OD1{ND6xPVI5KM7:TR?=	NFG4bVhUSU6JRWK=
L-428	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXtU\|BuUUN3ME2yOE42PzlzIN88US=>	MonHV2FPT0WU
NCI-H520	M{CyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXnWYQ2UUN3ME2yOE45QDZzIN88US=>	NWDSVmFtW0GQR1XS
COLO-792	NIPa[\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjJ[lV6UUN3ME2yOU4zPzN{IN88US=>	MWrTRW5ITVJ?
NB12	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nTXmlEPTB;MkWuNlk1PyEQvF2=	M{fPdHNCVkeHUh?=
GAK	M1[x[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfNTWM2OD1{NT6yPVY{KM7:TR?=	MlfIV2FPT0WU
SW780	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXP0RXlSUUN3ME2yOU4{OjZ2IN88US=>	NGLrTYdUSU6JRWK=
GB-1	NYrsTY5kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTJ3LkSwOlkh\|ryP	MUDTRW5ITVJ?
P12-ICHIKAWA	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXHTWM2OD1{NT60O\|g2KM7:TR?=	NGnBblNUSU6JRWK=
NCI-H1651	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTJ3LkW5O{DPxE1?	MkL4V2FPT0WU
KE-37	Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTJ3LkezNVUh\|ryP	MXLTRW5ITVJ?
CCRF-CEM	M3TRcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHVNGN3UUN3ME2yOU46PjdizszN	MnXoV2FPT0WU
SF295	NUW5NJp3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWL0R2tpUUN3ME2yOk4xPDJ3IN88US=>	NE\F[4FUSU6JRWK=
G-361	MlfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkS1TWM2OD1{Nj6xNFI4KM7:TR?=	NF\weY5USU6JRWK=
HOP-92	NVzvNZA6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDRTGVKSzVyPUK2MlEzOjZizszN	MX;TRW5ITVJ?
UMC-11	M{O0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHn1V3pKSzVyPUK2MlQ2OTRizszN	NIrRZnVUSU6JRWK=
IST-SL1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TPWGlEPTB;Mk[uOlU6OSEQvF2=	M1v6eXNCVkeHUh?=
TE-11	NWK4fVNGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTJ4Lke3OVIh\|ryP	NVzxPI9oW0GQR1XS
NCI-H1304	NHzydoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fKPWlEPTB;Mk[uPVExQCEQvF2=	MorFV2FPT0WU
SJSA-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInjbW9KSzVyPUK3MlAyPzZizszN	MnrkV2FPT0WU
BCPAP	NY\y[YlVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zob2lEPTB;MkeuNVM4KM7:TR?=	MmXBV2FPT0WU
HTC-C3	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nET2lEPTB;MkeuNlU3OSEQvF2=	MVfTRW5ITVJ?
EW-16	MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTJ5LkK5OFch\|ryP	NYj3enNDW0GQR1XS
HT-144	MknqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlrpTWM2OD1{Nz60NFMzKM7:TR?=	NVezTVJUW0GQR1XS
MHH-ES-1	NVvxenlIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjp[YtyUUN3ME2yO{41PDR5IN88US=>	Mnm4V2FPT0WU
T98G	MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrBTWM2OD1{Nz61PFQ3KM7:TR?=	MYLTRW5ITVJ?
RPMI-8866	NF\Jb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHXU\|d[UUN3ME2yO{44PTZ{IN88US=>	MYnTRW5ITVJ?
BEN	MoDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fW[mlEPTB;MkeuPFUyPyEQvF2=	NWnvdYtWW0GQR1XS
MDA-MB-231	NYHSWnRxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTJ6LkK3PVUh\|ryP	M2LzSXNCVkeHUh?=
HuH-7	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTJ6LkSwNlgh\|ryP	MXvTRW5ITVJ?
SK-N-FI	NEfxc3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\xe5ZKSzVyPUK4MlQ{OyEQvF2=	MkHTV2FPT0WU
AN3-CA	NIWyPFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn2wTWM2OD1{OD60N\|k2KM7:TR?=	M4HQTHNCVkeHUh?=
EGI-1	M3jrNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHRTWM2OD1{OD61PVI5KM7:TR?=	NXXJO3R3W0GQR1XS
697	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTJ6Lk[zN\|Eh\|ryP	M4SxVnNCVkeHUh?=
TCCSUP	M33qeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlXsTWM2OD1{OD62OFE5KM7:TR?=	NV64NpdnW0GQR1XS
GR-ST	NYjUXIVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTJ6Lk[2PVYh\|ryP	M1OxVXNCVkeHUh?=
SK-N-DZ	MlrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nzXmlEPTB;MkiuOlg5PSEQvF2=	NEnoTppUSU6JRWK=
MIA-PaCa-2	NXnoTmRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoP4TWM2OD1{OD63PVU6KM7:TR?=	MkPJV2FPT0WU
IGR-1	NIXoWJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Hhc2lEPTB;MkiuPFg4PCEQvF2=	MYrTRW5ITVJ?
BFTC-905	M2r4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzCOG1XUUN3ME2yPU4zPzB3IN88US=>	NYfFXlNZW0GQR1XS
NCI-H1581	MkfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfTdHRKSzVyPUK5MlMyPDVizszN	Mn3YV2FPT0WU
RD	NH;RUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHBNZhOUUN3ME2yPU42OjN\|IN88US=>	NUL3PFRWW0GQR1XS
SF268	NEOzOoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTJ7LkW5N\|Eh\|ryP	M1;menNCVkeHUh?=
SHP-77	NWe5XGpvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HvTGlEPTB;MkmuOlE5OiEQvF2=	Mnj4V2FPT0WU
D-566MG	NHXJb5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzj[Xg4UUN3ME2yPU46Ozl\|IN88US=>	MULTRW5ITVJ?
TGBC1TKB	NE\uT\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7RTWM2OD1\|MD6xNlM5KM7:TR?=	MULTRW5ITVJ?
MEL-HO	NXntcpk{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGT5Z5pKSzVyPUOwMlE1OjNizszN	MlrqV2FPT0WU
SJRH30	M2\2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jm[2lEPTB;M{CuNlExQCEQvF2=	MVjTRW5ITVJ?
D-336MG	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\1TWM2OD1\|MD6yPFkzKM7:TR?=	NX\XTXo1W0GQR1XS
C3A	M1jTWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LlZmlEPTB;M{CuNlkzPyEQvF2=	NFLBTFFUSU6JRWK=
Calu-6	M17kfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1nYc2lEPTB;M{CuNlk3OyEQvF2=	M4LHW3NCVkeHUh?=
MZ1-PC	NF2zV\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTNyLkO5N{DPxE1?	NXv3UHNtW0GQR1XS
KYSE-70	MojMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTpXY1uUUN3ME2zNE42OTF2IN88US=>	M{XmNHNCVkeHUh?=
CAPAN-1	M4\XT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTmelZRUUN3ME2zNE42OThzIN88US=>	NID1bZFUSU6JRWK=
DK-MG	NX3YSYtsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTNyLkW0OVYh\|ryP	NIWwOFJUSU6JRWK=
SK-HEP-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPpTWM2OD1\|MD62N\|I3KM7:TR?=	MljlV2FPT0WU
MS-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTNyLki4PFkh\|ryP	NFTZbnZUSU6JRWK=
GI-ME-N	M{DTc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvkTWM2OD1\|MT6wOVcyKM7:TR?=	NGfLZ2ZUSU6JRWK=
NCI-H510A	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3DVGpKSzVyPUOxMlQxODZizszN	M4TkUHNCVkeHUh?=
NB17	MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfRTWM2OD1\|MT61NVg2KM7:TR?=	MXvTRW5ITVJ?
639-V	NFW3OpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;JXHljUUN3ME2zNU42OjR\|IN88US=>	M4fHOnNCVkeHUh?=
CAL-51	NFS0WYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\KPIRKUUN3ME2zNU42PjZ5IN88US=>	MnLwV2FPT0WU
HGC-27	NFeyUJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TZXWlEPTB;M{GuOVg4OyEQvF2=	MVvTRW5ITVJ?
GOTO	MkL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTNzLki1NFYh\|ryP	MmX1V2FPT0WU
ChaGo-K-1	MkGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jCR2lEPTB;M{KuNFA4KM7:TR?=	M37kTXNCVkeHUh?=
RO82-W-1	M1LQcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXJdmhKSzVyPUOyMlE3ODRizszN	MojlV2FPT0WU
SH-4	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfGWllKSzVyPUOyMlE5PThizszN	NUTY[oNEW0GQR1XS
A204	MknKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTN{LkWwOlkh\|ryP	NIjPWlNUSU6JRWK=
DMS-273	NWezdHlzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnGWHc1UUN3ME2zNk42OzJ{IN88US=>	M3;nb3NCVkeHUh?=
KGN	NHGyXHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3ToTmlEPTB;M{KuOlM{KM7:TR?=	MonoV2FPT0WU
SK-MEL-2	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTN{Lk[1Nlch\|ryP	MoK3V2FPT0WU
NCI-H2228	NHyxeYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vFWGlEPTB;M{KuOlYxOiEQvF2=	NVzwSXdCW0GQR1XS
MKN28	MmXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHW3VmxKSzVyPUOyMlc5OzhizszN	M17kTnNCVkeHUh?=
H-EMC-SS	M3Oze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTN{Lkm2O\|gh\|ryP	NIf6d\|RUSU6JRWK=
ATN-1	NES4e2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTN\|LkG0NVYh\|ryP	M33iS3NCVkeHUh?=
D-263MG	NV;HbnU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHe2NotKSzVyPUOzMlg{PzhizszN	NH[0RotUSU6JRWK=
LU-135	M2C1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PpVGlEPTB;M{OuPFgzQSEQvF2=	MXjTRW5ITVJ?
C8166	MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVnNTVM5UUN3ME2zN{45QDV2IN88US=>	MWrTRW5ITVJ?
T-24	NX7C[IxlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NELkSmVKSzVyPUO0MlAzODVizszN	M{DpVXNCVkeHUh?=
Mewo	NWrjNW1HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTN2LkGzOFkh\|ryP	MUXTRW5ITVJ?
22RV1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzNdG5KSzVyPUO0MlE4PTRizszN	NFzRSlFUSU6JRWK=
KM-H2	M{X1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIn2SpJKSzVyPUO0MlE4PzlizszN	M2iyWXNCVkeHUh?=
NCI-H2122	M{Hkc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFqyZ3ZKSzVyPUO0MlM1PzFizszN	NXzsbmRvW0GQR1XS
ABC-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXyTWM2OD1\|ND6zOlk{KM7:TR?=	NHHRWGFUSU6JRWK=
NCI-H1355	Ml7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTN2LkO4PFkh\|ryP	MXzTRW5ITVJ?
NOMO-1	MoHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH3uT4hKSzVyPUO0MlU4ODNizszN	M{D5PHNCVkeHUh?=
MZ7-mel	MkHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7uPWxKSzVyPUO0MlY1QDdizszN	M1zLbHNCVkeHUh?=
NCI-H810	NEjSNIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\NUYtKSzVyPUO0MlczPzhizszN	NH\QcJdUSU6JRWK=
D-392MG	M1fvdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLETWM2OD1\|NT6wOVY2KM7:TR?=	NYT5cXRpW0GQR1XS
LB771-HNC	MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\xUGlEPTB;M{WuNVY2QCEQvF2=	M2nRNXNCVkeHUh?=
COLO-679	M3\qUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\s[mpzUUN3ME2zOU4{QDhizszN	M1jtRnNCVkeHUh?=
SK-PN-DW	NEL3dFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInLdWNKSzVyPUO1MlQ{PjlizszN	M2DMNHNCVkeHUh?=
VA-ES-BJ	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7kTWM2OD1\|NT60OlQ6KM7:TR?=	NIG4[3JUSU6JRWK=
KNS-42	M{exWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnmzTWM2OD1\|NT61PFI3KM7:TR?=	M2LvOnNCVkeHUh?=
RVH-421	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTN3Lke2OFUh\|ryP	NFTLXHdUSU6JRWK=
P30-OHK	M1rpZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnu4TWM2OD1\|NT64O\|UzKM7:TR?=	NVrOeWNuW0GQR1XS
G-402	M{LmfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTN3Lkm4Olch\|ryP	MWHTRW5ITVJ?
S-117	NFS3TJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfVTWM2OD1\|Nj6zNFA5KM7:TR?=	NU\6UXgzW0GQR1XS
RXF393	MkfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTlTWM2OD1\|Nj6zO\|g2KM7:TR?=	MVfTRW5ITVJ?
LCLC-103H	M{HpbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TzcmlEPTB;M{[uO\|gxOyEQvF2=	MX;TRW5ITVJ?
U-118-MG	NVW1cYlbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3z0WGlEPTB;M{[uPFg1PyEQvF2=	NW\JbYdRW0GQR1XS
8-MG-BA	M4PIe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnETWM2OD1\|Nj65OFg{KM7:TR?=	NVLPemdPW0GQR1XS
MFH-ino	NXrxWW1pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjsOm81UUN3ME2zO{4{OzdzIN88US=>	Mn:5V2FPT0WU
NCI-H23	Ml;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\iOHVxUUN3ME2zO{41OTl4IN88US=>	MkTJV2FPT0WU
NCI-H446	M1nr[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTN5LkS4OlIh\|ryP	NEmyUG5USU6JRWK=
LU-99A	NHnhRplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGiyTlBKSzVyPUO3MlU4OzFizszN	NVXIWHM6W0GQR1XS
KP-N-YN	Ml20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVu5N25bUUN3ME2zO{43OTl3IN88US=>	MkDaV2FPT0WU
SCC-9	MljnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmTwTWM2OD1\|Nz63PFM5KM7:TR?=	MkDDV2FPT0WU
EFM-19	M4XJSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HZcmlEPTB;M{euO\|k3PyEQvF2=	MYjTRW5ITVJ?
A427	NXXrSJpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LjNmlEPTB;M{euPVExPyEQvF2=	M3;SXHNCVkeHUh?=
LB831-BLC	MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTFelJKSzVyPUO4MlYxOzlizszN	MYjTRW5ITVJ?
HOS	NIfVfIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rIdGlEPTB;M{muOlI4OyEQvF2=	MmPXV2FPT0WU
LAN-6	MnzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\tSGlEPTB;NECuNFEyOiEQvF2=	Ml3mV2FPT0WU
U251	NF7HW3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTRyLkSwOVQh\|ryP	NHzGWoRUSU6JRWK=
SNU-387	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX3R[IhMUUN3ME20NE41PTV\|IN88US=>	NIrER\|dUSU6JRWK=
DMS-79	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInqXoxKSzVyPUSwMlU5QDlizszN	NYXEb4JRW0GQR1XS
SK-LU-1	NV7iemhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rKVmlEPTB;NECuOlU3QCEQvF2=	MV\TRW5ITVJ?
HT	NGrRb5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoG0TWM2OD12MD62OlM6KM7:TR?=	MVnTRW5ITVJ?
KP-N-YS	NGnwbZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2CzXGlEPTB;NECuOlc3QCEQvF2=	MlzqV2FPT0WU
DMS-114	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTRyLkizO\|Qh\|ryP	M{GyW3NCVkeHUh?=
HUTU-80	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zEdWlEPTB;NEGuNFU3QSEQvF2=	Ml\2V2FPT0WU
ONS-76	NW\4e5g1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHmSGpKSzVyPUSxMlQ4ODlizszN	MUfTRW5ITVJ?
A673	M1HBT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjGZpBKSzVyPUSxMlUyPTdizszN	NYLnSGJOW0GQR1XS
HPAF-II	NVO0WJdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmiyTWM2OD12MT62O\|A6KM7:TR?=	MVLTRW5ITVJ?
UACC-257	MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDKe3lKSzVyPUSxMlc{PjlizszN	NUn4fI5uW0GQR1XS
EW-22	M3rSZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLrTWM2OD12MT64Olk4KM7:TR?=	NVzmN4dWW0GQR1XS
NCI-H1755	NVfBOHNzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDmXnh1UUN3ME20NU45PzJ3IN88US=>	NUL0W216W0GQR1XS
KYSE-150	M4PwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1:5T2lEPTB;NEKuNVc5OiEQvF2=	MVXTRW5ITVJ?
CGTH-W-1	NXH1N\|duT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVu2RnU{UUN3ME20Nk41QTV3IN88US=>	M{CzTHNCVkeHUh?=
NB13	MlXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTR{Lk[yNVch\|ryP	NEPGPXVUSU6JRWK=
SW872	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7TXHJLUUN3ME20Nk43OzNzIN88US=>	MlPpV2FPT0WU
KP-4	MkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTR{Lki4N\|Ih\|ryP	MXzTRW5ITVJ?
HCC38	NFG4c3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWC5WJY6UUN3ME20Nk46PjF6IN88US=>	MX;TRW5ITVJ?
BB49-HNC	M1;vVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYD5e2ZDUUN3ME20N{4zOzV4IN88US=>	NGL5Z45USU6JRWK=
CAL-62	NXvHdJFkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTR\|LkSwNlgh\|ryP	MoHTV2FPT0WU
NCI-H2029	Mne5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfSTWM2OD12Mz61OVgyKM7:TR?=	MlWzV2FPT0WU
M14	NFrQSmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLLOY5KSzVyPUS0MlE{OzJizszN	MmDFV2FPT0WU
COLO-680N	NWLlboIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3IW2NKSzVyPUS0MlM{QSEQvF2=	NWTvblkyW0GQR1XS
Hs-578-T	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37oWmlEPTB;NEWuNFI6PCEQvF2=	NWDsPXlJW0GQR1XS
MSTO-211H	Ml:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvpe5M1UUN3ME20OU46PDh{IN88US=>	NYfHNGFtW0GQR1XS
EW-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTR3Lkm2PFkh\|ryP	NFfReJRUSU6JRWK=
SW948	MkLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTR4LkS0OlIh\|ryP	M2CwS3NCVkeHUh?=
NCI-H460	NH:3[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTR4LkWyN{DPxE1?	MnrwV2FPT0WU
CAS-1	MnnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEn2V4dKSzVyPUS2Mlc4ODFizszN	MlT3V2FPT0WU
TGBC11TKB	Mnj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFv2RmtKSzVyPUS3MlE4PzdizszN	NVLweVhVW0GQR1XS
HD-MY-Z	Mnz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvXVYxGUUN3ME20PE44QDZizszN	M2rOPHNCVkeHUh?=
NCI-H226	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfVVlZpUUN3ME20PU44Pzh3IN88US=>	M3iweHNCVkeHUh?=
PA-1	NF\nNIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTR7LkizN\|Uh\|ryP	MlfQV2FPT0WU
LB2518-MEL	MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7xeohKSzVyPUS5Mlg4OjNizszN	NVX2UYRGW0GQR1XS
A101D	MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTR7Lkm0NlUh\|ryP	M3TNN3NCVkeHUh?=
NCI-H2087	M4D1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PxS2lEPTB;NEmuPVY5OiEQvF2=	M4DrSHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	CIP2A / p-AKT / AKT / PARP; PubMed: 25537503 Oncotarget Time-dependent effects of afatinib on CIP2A, p-AKT and apoptosis-related proteins in the sensitive H358 and resistant H460 cells. Cells were exposed to 10 μM afatinib for up to 48 hours. Immunoblots were scanned and quantitated to determine the ratio of the level of CIP2A to actin. Data are mean ± SD. n = 3 for the different time intervals. p-EGFR / p-IGF1R / p-ERK / p-AKT; PubMed: 26052929 Mol Carcinog Effects of afatinib on EGFR and IGF1R Signaling Pathways. H1975 cells were treated with afatinib with various doses and cell lysates were subjected to Western blot analysis. Afatinib effectively inhibits p-EGFR and p-ERK while p-AKT was partially inhibited. IGF1R phosphorylation was increased upon afatinib treatment in H1975 cells. p-VEGFR2 / VEGFR2 / JAG1 / DLL4 / NICD1 ; PubMed: 28533486 Oncotarget HUVECs were cultured in the presence of Vatalanib (100 nM) or DBZ (10 nM) for 1 h and then treated for 15 min with rhgal-3 (37 nM) and cultured for additional 6 hrs. After this period, the total protein was isolated and the protein levels of galectin-3, NICD1, DLL4, JAG1, VEGFR2 and VEGFR2-p were assessed by Western blot. β-actin was used as a loading control.	25537503 26052929 28533486
Growth inhibition assay	Cell apoptosis; PubMed: 25537503 Oncotarget Dose-dependent effects of afatinib on apoptosis. Data are mean ± SD. n = 3 for each concentration. , p < 0.05, *, p < 0.01, vs. no afatinib. Cell viability; PubMed: 26515464 Oncotarget A. MTS assay for Ba/F3 cells harboring EGFR exon 19 deletion and L858R. The proportional cell viability is shown. B. MTS assay for Ba/F3 cells harboring EGFR exon 19 deletion+T790M and L858R+T790M. The proportional cell viability is shown. C. MTS assay for Ba/F3 cells harboring wild type EGFR. The proportional cell viability is shown. Erlotinib, afatinib, osimertinib, and rociletinib were used as EGFR-TKIs. Error bars indicate standard deviation.	25537503 26515464
Immunofluorescence	p65; PubMed: 26317651 Oncotarget Effects of different treatments on the nuclear translocation of the NF-κB subunit p65. A2780T cells were treated with 2.5 μM afatinib for 48 hours, or 10 μM PDTC for 2 hours. Subsequently, the NF-κB subunit p65 (red) was localized by immunofluorescence and a confocal microscopy. Nuclei were stained with DAPI (blue). Scale bar = 10 μM. vacuoles; PubMed: 29713246 Cancer Cell Int Autophagy activation upon treatment with Afatinib and Sorafenib was validated using immunofluorescence in order to visualize a creation of autophagosomes; ×60 magnification. DMSO treatment was used as control. Green—autophagy vacuoles; Blue—Hoechst, nuclear staining.	26317651 29713246

In vivo

Daily oral administration of BIBW2992 at 20 mg/kg for 25 days results in dramatic tumor regression with a cumulative treated/control tumor volume ratio (T/C ratio) of 2%. Reduced phosphorylation of EGFR and AKT is confirmed by immunohistochemical staining of tissue sections. Therefore, like lapatinib and neratinib, BIBW2992 is a next generation tyrosine kinase inhibitor (TKI) that inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases irreversibly. BIBW2992 is not only active against EGFR mutations targeted by first generation TKIs like Erlotinib or Gefitinib, but also against those insensitive to these standard therapies. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro kinase activity assays: The wild type tyrosine kinase domain of the human EGFR as well as that of the EGFR L858R/T790M double mutant are fused to Glutathione-S-transferase (GST), and extracted. Enzyme activity is then assayed in the presence of the inhibitor BIBW2992, serially diluted in 50% DMSO. A random polymer pEY (4:1) is used as substrate and biotinylated pEY (bio-pEY) is added as a tracer substrate. The kinase domain of HER2 is cloned using the baculovirus system and extracted similarly to that of EGFR kinase. Details of assays for EGFR, HER2, SRC, BIRK and VEGFR2 kinase activity are available in Supplementary information.
Cell Research: ^[1]	- Collapse Cell lines: NSCLC cells Concentrations: 0-10 μM Incubation Time: 1 hour Method: 1 × 10⁴ NSCLC cells are transferred into each well of a 96-well plate and cultured overnight in serum-free media for the EGFR phosphorylation assay. After addition of BIBW2992 on the next day, the plates are incubated at 37 °C for 1 hour. EGF-stimulation is done using 100 ng/mL for 10 min at room temperature. Cells are washed with ice cold PBS, extracted with 120 μL HEPEX buffer per well and shaken at room temperature for 1 hour. In all 2 × 10⁴ cells per well is used for the HER2 phosphorylation assay. Streptavidin precoated plates are coated with anti-EGFR-biotin at 1:100 dilution in blocking buffer and c-erb2/HER2 oncoprotein Ab-5(Clone N24)-Biotin. Cell extracts is then transferred to the antibody-coated wells and incubated at room temperature for 1 hour. Extinction is measured at 450 nm. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Athymic NMRI-nu/nu female mice Formulation: In 0.5% methocellulose-0.4% polysorbate-80 (Tween 80) Dosages: 20 mg/kg Administration: Oral administration (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	97 mg/mL (199.61 mM)
	Ethanol	15 mg/mL (30.86 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Afatinib (BIBW2992) SDF

Molecular Weight	485.94
Formula	C₂₄H₂₅ClFN₅O₃
CAS No.	439081-18-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A
Smiles	CN(C)C/C=C/C(=O)NC1=CC2=C(NC3=CC=C(F)C(=C3)Cl)N=CN=C2C=C1OC4CCOC4

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03711422	Not yet recruiting	Drug: Afatinib	Non-small Cell Lung Cancer\|Leptomeningeal Disease\|Central Nervous System Metastases	National Cancer Centre Singapore	October 2018	Phase 1
NCT03083678	Recruiting	Drug: Afatinib	Chordoma	Leiden University Medical Center\|Chordoma Foundation\|Boehringer Ingelheim	June 21 2018	Phase 2
NCT03370770	Active not recruiting	Drug: Afatinib\|Drug: Osimertinib	Carcinoma Non-Small-Cell Lung	Boehringer Ingelheim	December 28 2017	--
NCT02423525	Recruiting	Drug: Afatinib	Brain Cancer	Santosh Kesari\|Boehringer Ingelheim\|John Wayne Cancer Institute	December 2016	Phase 1
NCT02695290	Terminated	Drug: Afatinib	Carcinoma Non-Small-Cell Lung\|ErbB Receptors	Boehringer Ingelheim	March 17 2016	Phase 4
NCT02171741	Completed	Drug: BIBW 2992\|Drug: Docetaxel	Neoplasms	Boehringer Ingelheim	April 2005	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommendation about reconstitution of the compound for in vivo animal study?
Answer:
For in vivo experiment of afatinib, we recommend 0.5% methylcellulose/0.2% Tween 80 as vehicle.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Selective EGFR Inhibitor

Erlotinib HCl (OSI-744) : EGFR-selective, IC50=2 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.
Classic EGFR Inhibitor

WZ4002 : Mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM.

Related EGFR Products

Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.
Gefitinib (ZD1839)

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

Features:A potent EGFR tyrosine kinase inhibitor.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib

Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Choose Your Country or Region

By Signaling Pathways

By product type

Afatinib (BIBW2992)